Antineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsChemotherapy, AdjuvantDoxorubicinCyclophosphamideCombined Modality TherapyT-Lymphocytes, CytotoxicCisplatinTreatment OutcomeNeoplasmsBreast NeoplasmsLung NeoplasmsEtoposideDrug Resistance, NeoplasmDisease-Free SurvivalClinical Trials as TopicPrognosisDrug Administration ScheduleMethotrexateNeoplasm StagingNeutropeniaAngiogenesis InhibitorsSurvival AnalysisDeoxycytidineSurvival RateLymphoma, Non-HodgkinAntibiotics, AntineoplasticNeoplasm Recurrence, LocalAntibodies, Monoclonal, HumanizedAcneiform EruptionsAntimetabolites, AntineoplasticTaxoidsCell Line, TumorClinical Trials, Phase III as TopicPaclitaxelOvarian NeoplasmsNeoplasm MetastasisAntibodies, MonoclonalOrganoplatinum CompoundsCarcinoma, Non-Small-Cell LungNeoadjuvant TherapyTime FactorsMolecular Targeted TherapyDrug SynergismClinical Trials, Phase I as TopicDacarbazineMitoxantroneApoptosisLeukemia, Myeloid, AcuteClinical Trials, Phase II as TopicCell SurvivalLymphomaImmunotherapyCytotoxicity, ImmunologicVincristineGranulocyte Colony-Stimulating FactorAdenocarcinomaBrain NeoplasmsThrombocytopeniaFollow-Up StudiesXenograft Model Antitumor AssaysDose-Response Relationship, DrugBenzenesulfonatesTumor Cells, CulturedNiacinamideProtein Kinase InhibitorsCarboplatinBone MarrowVinblastineFluorouracilRandomized Controlled Trials as TopicLiver NeoplasmsAntibodies, Monoclonal, Murine-DerivedMultiple MyelomaTumor Markers, BiologicalDisease ProgressionInduction ChemotherapyRecurrencePhenylurea CompoundsPore Forming Cytotoxic ProteinsAntineoplastic Agents, HormonalMice, NudeCell ProliferationAntineoplastic Agents, PhytogenicQuinazolinesIfosfamideProspective StudiesRecombinant ProteinsTamoxifenProstatic NeoplasmsAntineoplastic Agents, AlkylatingRandom AllocationBleomycinCytarabineCytotoxinsAnthracyclinesDrug Screening Assays, AntitumorChemotherapy, Cancer, Regional PerfusionSalvage TherapyRetrospective Studies